• 473 Citations
  • 9 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Debendra Pattanaik is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Systemic Scleroderma Medicine & Life Sciences
Rheumatoid Arthritis Medicine & Life Sciences
Differential Diagnosis Medicine & Life Sciences
Psoriatic Arthritis Medicine & Life Sciences
Intravenous Immunoglobulins Medicine & Life Sciences
LY2439821 Medicine & Life Sciences
Immunologic Factors Medicine & Life Sciences
Autoantibodies Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2003 2019

  • 473 Citations
  • 9 h-Index
  • 10 Article
  • 10 Review article
  • 4 Letter
  • 1 Comment/debate

Common Variable Immune Deficiency and Associated Complications

Gupta, S., Pattanaik, D. & Krishnaswamy, G., Sep 1 2019, In : Chest. 156, 3, p. 579-593 15 p.

Research output: Contribution to journalReview article

Common Variable Immunodeficiency
Intravenous Immunoglobulins
1 Citation (Scopus)

Nitrate allergy and desensitization in a patient with refractory angina

Kessler, S. G., Gillion, A. R., Pattanaik, D. & Rogers, K., Apr 1 2019, In : Journal of Allergy and Clinical Immunology: In Practice. 7, 4, p. 1322-1323 2 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Cellular and molecular mechanisms of anti-phospholipid syndrome

Radic, M. & Pattanaik, D., May 7 2018, In : Frontiers in immunology. 9, MAY, 969.

Research output: Contribution to journalReview article

Antiphospholipid Syndrome
Antigen-Antibody Complex
Venous Thrombosis
7 Citations (Scopus)

The changing face of anaphylaxis in adults and adolescents

Pattanaik, D., Lieberman, P., Lieberman, J., Pongdee, T. & Keene, A. T., Nov 1 2018, In : Annals of Allergy, Asthma and Immunology. 121, 5, p. 594-597 4 p.

Research output: Contribution to journalArticle

International Classification of Diseases
42 Citations (Scopus)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

on behalf of the EMBODY Investigator Group, Feb 1 2017, In : Arthritis and Rheumatology. 69, 2, p. 362-375 14 p.

Research output: Contribution to journalArticle

Systemic Lupus Erythematosus